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Abstract: Background: Greater Trochanter Pain Syndrome (GTPS) is the main reason for recalcitrant
lateral hip pain. Gluteus medius and minimus tendinopathy plays a key role in this setting.
An injectable medical compound containing collagen type I (MD-Tissue, Guna) has been produced
with the aim to counteract the physiological and pathological degeneration of tendons. In this study
we aimed at characterizing the effect of this medical compound on cultured human gluteal tenocytes,
focusing on the collagen turnover pathways, in order to understand how this medical compound
could influence tendon biology and healing. Methods: Tenocytes were obtained from gluteal tendon
fragments collected in eight patients without any gluteal tendon pathology undergoing total hip
replacement through an anterior approach. Cell proliferation and migration were investigated by
growth curves and wound healing assay, respectively. The expression of genes and proteins involved
in collagen turnover were analysed by real-time PCR, Slot blot and SDS-zymography. Results: Our
data show that tenocytes cultured on MD-Tissue, compared to controls, have increased proliferation
rate and migration potential. MD-Tissue induced collagen type I (COL-I) secretion and mRNA levels
of tissue inhibitor of matrix metalloproteinases (MMP)-1 (TIMP-1). Meanwhile, lysyl hydroxylase
2b and matrix metalloproteinases (MMP)-1 and -2, involved, respectively, in collagen maturation
and degradation, were not affected. Conclusions: Considered as a whole, our results suggest that
MD-Tissue could induce in tenocytes an anabolic phenotype by stimulating tenocyte proliferation and
migration and COL-I synthesis, maturation, and secretion, thus favouring tendon repair. In particular,
based on its effect on gluteal tenocytes, MD-Tissue could be effective in the discouraging treatment of
GTPS. From now a rigorous clinical investigation is desirable to understand the real clinical potentials
of this compound.
Keywords: tendinopathy; Greater Trochanter Pain Syndrome; tendon; collagen turnover; matrix
metalloproteinases; cytoskeleton; focal adhesion
1. Introduction
Tendinopathy is a chronic, painful condition affecting tendons, characterized by histological
modifications such as collagen fibril disorganization, increased proteoglycan and glycosaminoglycan
content, and increased non-collagen extracellular matrix components, hypercellularity, and
neovascularization [1]. Pain associated with tendinopathy is a very common cause of disability.
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Pain around the greater trochanter was in the past attributed to trochanteric bursitis, but different
studies ([2,3] and references therein) have suggested that this condition is mainly determined by a
tendinopathy of the gluteus medius or minimus tendons, known as Greater Trochanter Pain Syndrome
(GTPS). GTPS is a clinical condition characterized by pain and tenderness at or around the greater
trochanter, pain with activities such as walking and stair climbing, and lying on the affected side at
night [4]. Even if it is a common condition, few effective treatments are available in the clinical practice,
and are often empirical [5]. Therefore, the interest in biological and regenerative therapies aiming to
improve tendon healing, such as platelet-rich plasma (PRP) or hyaluronic acid [6], has grown during
the last decade.
Treatment of tendinopathy, including Greater Trochanter Pain Syndrome and others, remains a
big problem for clinicians, because its pathogenesis is still largely misunderstood, and many treatments
have no real evidence. The management of GTPS is traditionally first conservative, including rest,
ice-packs, non-steroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and local corticosteroids
injections. However, recent studies found little evidence to support physical therapy or exercise
programs for gluteal tendinopathy [7]. Corticosteroid injections are widely used despite controversies
regarding the use of glucocorticoid injections for the treatment of tendinopathy. A recent systematic
review of literature showed that they provide short-term pain relief, but no long-term benefits [5,8].
No statistically significant differences have been reported after 1 year compared to oral NSAIDs.
Some authors reported about the use of Extracorporeal Shock Wave Therapy (ESWT) with good
results [9], but the evidence of most of these studies is low, and no level I studies are published in
literature. Therefore, biological therapies aiming to improve tendon healing become very attractive.
The only level I study on the PRP showed an improvement of pain and mHHS at 12 weeks after a
single injection of PRP, compared to a single injection of corticosteroids [10]. In a recent case series,
promising results have been reported with autologous tenocyte injection [11]. However, there is still
little evidence to support the use of biological therapies for treatment of GTPS [12].
Tendons play key functions in musculoskeletal system in transferring forces generated by muscle
contraction to the skeleton. Their mechanical properties are based on the underlying extracellular
matrix (ECM) structure and composition, mainly consisting of type I collagen (COL-I) [13–15].
Tenocytes are tendon specialized fibroblasts interspersed between collagen fibers, responsible for
the metabolic activity and structure of tendon. They are involved in collagen turnover pathways
and act as mechanosensors playing key roles in modifying gene expression for ECM components in
response to mechanical forces acting on tendons [14,16,17].
The aim of this study was to investigate in vitro the effect of MD-Tissue®, an injectable
collagen-based medical compound with therapeutic potential (registered as a medical device in
different countries) containing swine collagen as main component, on human tenocytes, with particular
attention on collagen turnover pathways, in order to understand the molecular mechanisms triggered
by this medical compound and, therefore, how it could act in favoring tendon homeostasis and repair.
We were particularly interested in clinical situations such as GTPS; for this purpose we analyzed
gluteal tenocytes.
The production process of MD-Tissue by the manufacturer allows to obtain a pure product with a
standardized molecular weight, having the chemical-physical characteristics to guarantee safety in
clinical use. No side effects, allergic reactions, nor drug interactions have been observed. Clinical data
reported that treatment with MD-Knee, a collagen-based medical compound similar to MD-Tissue, for
up to 6 months was generally well tolerated, and no systemic adverse events or septic complications
were observed [18,19].
The characterization in vitro of the molecular mechanisms triggered by MD-Tissue will be pivotal
to plan specific clinical trials.
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2. Materials and Methods
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Local Ethics Committee (San Raffaele Hospital Ethical Committee, Milan, Italy) of the
coordinating Institution (IRCCS Policlinico San Donato, Milan, Italy) (63/INT/2017) Inclusion and
exclusion criteria are listed in Table 1.
Table 1. Eligibility Criteria.
Inclusion Criteria Exclusion Criteria
Age ranging 18–70 years. Patients diagnosed of great trochanter tendinopathy
Indication for total hip arthroplasty. Patients affected by genetic collagen disorders.
Patients who signed written informed consent for
the surgery.
Patients diagnosed of spondyloarthritis with
involvement of the affected hip.
Patients able to understand the study conditions
and willing to participate for its entire duration. Patients affected by psoriatic arthritis.
Drug-addicted
Alcohol-addicted
Psychiatric disorders
Clinical conditions which could compromise the
results of the surgical procedure or of the follow-up.
Informed consent not accepted.
Pregnant or breastfeeding women.
Patients affected by diabetes mellitus.
Patients who had taken fluoroquinolones within
30 days before the surgery.
2.1. Samples
Fragments from human gluteal tendon were obtained from 8 patients (mean age 64.8 ± 7.2 years,
4 males and 4 females) without any gluteal tendon pathology and undergoing total hip replacement
through an anterior approach. For each sample we analyzed the mid-substance of the collected tendon,
representing the region with the typical structure of the dense regular connective tissue.
2.2. Cell Cultures
Tendon fragments were immediately washed in sterile PBS and plated in T25 flasks, incubated in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), antibiotics (100 U/mL penicillin, 0.1 mg/mL streptomycin), and ascorbic acid (200 µM)
at 37 ◦C in a humidified atmosphere containing 5% CO2. When tenocytes grew out from the explant,
they were trypsinized (0.025% trypsin-0.02% EDTA) for secondary cultures and plated in T75 flasks.
Viability was assessed by the Trypan blue exclusion method. For evaluations, confluent human
tenocytes were used between the fourth and fifth passage. For SDS-zymography cells were cultured
in serum-free DMEM. Tenocytes derived from each patients and cell supernatants were prepared in
duplicate and were analyzed after 24, 48, and 72 h.
2.3. Coating with MD-Tissue
MD-Tissue®, kindly provided by Guna (Milan, Italy), is an injectable medical compound based on
swine collagen (100 µg/2 mL ampoules). It contains ascorbic acid, magnesium gluconate, pyridoxin
hydrochloride, riboflavin, thiamine hydrochloride, NaCl and water as excipients. Swine collagen
is similar to human collagen and due to the high biocompatibility with humans and very low risk
of adverse effects, it has been used in various clinical fields. MD-Tissue is an injectable compound
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but we hypothesized that it could act as a mechanical scaffold to influence tenocyte metabolism.
Thus, MD-Tissue was used as a substrate for cell cultures. However, as previously demonstrated [20],
some of the collagen used for the coating in cell cultures comes out contributing to the mechanical
stimulation of tenocytes.
To obtain a thin coating, MD-Tissue (50 µg/mL) was added to multi-wells or T25 flasks (3 mL per
T25 flask and 6-well multi-well plates, ad 500 µL per 24-well multi-well plates). After an incubation of
at least 3–4 h at room temperature to ensure that collagen has adhered to the plastic, excess fluid was
removed from the coated surface that was dried for at least 2 h under the laminar flux hood. Coated
plastic was used immediately or stored at 4 ◦C.
Cells cultured on uncoated cell culture plastic (NC) were used as untreated controls.
2.4. Growth Curves
Cell growth was assessed by growth curves. Tenocytes were plated in triplicate samples in 6-well
multi-well plates at the same cell density (100,000 cells/well). Cell number was determined using a
Neubauer chamber after 24, 48, and 72 h in tenocytes in the proliferative phase.
2.5. Immunofluorescence Analysis
For fluorescence microscopy, tenocytes were cultured on uncoated (NC) or MD-Tissue coated
12-mm diameter round coverslips put into 24-well culture plates, as previously described [21].
Briefly, for actin cytoskeleton analysis, cells were incubated with 50 µM rhodamine-phalloidin
(Sigma-Aldrich, St. Louis, MO, USA) and for vinculin detection, cells were incubated for 1 h at
room temperature with the rabbit polyclonal antibody anti-vinculin (1:600 in PBS, Sigma-Aldrich,
St. Louis, MO, USA). The secondary antibody was an anti-rabbit/Alexa488 (1:500, Life Technologies,
Carlsbad, CA, USA). Cells were photographed by a digital camera connected to a Nikon Eclipse
80i microscope.
2.6. Real-Time PCR
Gene expression was analyzed by real-time RT-PCR as previously reported in samples
run in triplicate [22]. GAPDH was used as endogenous control to normalize the differences
in the amount of total RNA in each sample. The primers sequences were the following:
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH): sense CCCTTCATTGACCTCAACTACATG,
antisense TGGGATTTCCATTGATGACAAGC; Long lysyl hydroxylase 2 (LH2b): sense
CCGGAAACATTCCAAATGCTCAG, antisense GCCAGAGGTCATTGTTATAATGGG; Tissue
inhibitor of matrix metalloproteinase 1 (TIMP-1): sense GGCTTCTGGCATCCTGTTGTTG, antisense
AAGGTGGTCTGGTTGACTTCTGG; vinculin: sense GGAGGTGATTAACCAGCCAAT, antisense
AATGATGTCATTGCCCTTGC; Focal adhesion kinase (FAK): sense GTCTGCCTTCGCTTCACG,
antisense GAATTTGTAACTGGAAGATGCAAG; Nanog sense CCCCAGCCTTTACTCTTCCTA,
antisense CCAGGTTGAATTGTTCCAGGTC. Each sample was analyzed in triplicate in a Bioer
LineGene 9600 thermal cycler (Bioer, hangzhou, China) after 40 cycles. The cycle threshold (Ct) was
determined and gene expression levels relative to that of GAPDH were calculated. To confirm the
reliability of gene expression results, mRNA levels of target genes were normalized on a second
housekeeping gene, the 18s ribosomal RNA. The expression pattern obtained was similar (data
not shown).
2.7. Slot Blot
Collagen type I and III (COL-I, COL-III), matrix metalloproteinase (MMP)-1 protein levels
secreted by tenocytes were assessed in duplicate samples by Slot blot in serum free cell culture
medium, as previously detailed [21]. Membranes were incubated for 1 h at room temperature in
monoclonal antibody to COL-I (1:1000 in TBST) (Sigma-Aldrich, Milan, Italy), COL-III (1:2000 in TBST)
(Sigma-Aldrich, Milan, Italy), MMP-1 (1 µg/mL in TBST) (Millipore, Milan, Italy). Immunoreactive
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bands, revealed by the Amplified Opti-4CN substrate (Amplified Opti-4CN, Bio Rad, Italy), were
scanned densitometrically (UVBand, Eppendorf, Italy).
2.8. SDS-Zymography
SDS-zymography was used to analyze MMP-2 activity of secreted protein in cell culture medium,
as previously described [21]. MMP gelatinolytic activity, detected after staining the gels with Coomassie
brilliant blue R250 as clear bands on a blue background, were quantified by densitometric scanning
(UVBand, Eppendorf, Italy).
2.9. Wound Healing Assay
Cell migration in adult and aging tenocytes was analyzed by wound healing assay in uncoated
(NC) and MD-Tissue coated 6-wells multi-well plates [22]. The “scratch” was created in confluent
tenocytes using a p 200 pipet tip. After cell debris removal by DMEM washing, multi-well plates were
incubated at 37 ◦C and observed under an inverted microscope at different time points. Digital images
were captured by a digital camera after 0 and 24 h, and the size of the “scratch” was measured to
obtain the migration potential.
2.10. Statistical Analysis
Statistical analysis was performed using GraphPad Prism v 6.0 software (GraphPad Software
Inc., San Diego, CA 92108, USA). Data were obtained from two replicate experiments for each of the
patients-derived cell lines cultured in duplicate and were expressed as mean ± standard deviation
(SD). Comparison of groups was calculated using independent samples two-tailed t test. Differences
associated with p-values lower than 5%, at a confidence level of 95%, were to be considered significant.
3. Results
3.1. Cell Growth
Cell proliferation evaluated by growth curves showed that tenocytes cultured on uncoated (NC) or
MD-Tissue coated 6-well multi-well plates had the same proliferation rate after 24 and 48 h. By contrast,
cell proliferation significantly increased in tenocytes grown on MD-Tissue after 72 h (p < 0.05 vs. 72 h
NC) (Figure 1).
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3.2. Expression of Genes and Proteins Related to Collagen Turnover
Since it was demonstrated that, using different methods to isolate tenocytes from tendon
fragments, the obtained cell population can be a mixed population of terminally differentiated
tenocytes and progenitor cells [23], we first characterized our cells determining the expression of
Nanog, one of the main mesenchymal stem cell markers [24]. Adipose tissue-derived stem cells (ASCs)
(kindly provided by Dr. Anna Brini, University of Milan) were used as positive control. We found
that Nanog is almost undetectable in all the considered cell cultures obtained from tendon fragments,
while it is highly expressed in ASCs (Figure 2), showing that cells used in this study are mostly
differentiated tenocytes.
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Figure 2. Bar graphs showing mRNA levels for Nanog in adipose tissue-derived stem cells (ASCs) and
the eight cell cultures of tenocytes assess d by real-time PCR. Data were normal z on Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene expr ssion.
Collagen maturation was assessed by analyzing LH2b gene expression by real time PCR, involved
in cross-linking of newly synthetized collagen. LH2b mRNA levels were unaffected by MD-Tissue at
all the considered time p ints (Figure 3). Slot bl t analysis revealed that COL-I protein levels secreted
in cell culture medium by tenocytes cultured on MD-Tissue were increased (+25%, +19% and +18%,
respectively, for COL vs. NC after 24, 48 and 72 h). This increase was statistic lly significant in cells
cultured on COL, compared to NC, at all the co sidered time points (p < 0.005, p < 0.05 a d p < 0.05
for MD-Tissue vs. CT, respectively, at 24, 48 and 72 h) (Figure 4A,B). To demonstrate that collagen
expression detect d by Slot blot originates from tenocytes and not from the coating, we prepared Slot
blot to analyz COL-I expression in the same volume (100 µL) of tenocyte culture medium, DMEM
fr m a MD-Tissue coated well, DMEM o ly and TBS buffer. The result shows that an immunoreactive
band is detected only for ten cytes, demonstrating that collagen originates only from cells and not
from the coating (Figure 3C). By contrast, COL-III protein levels were similarly s creted by NC and
MD-Tissue tenocytes (data not shown).
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Collagen degradation analysis revealed that MMP-1 levels (Figure 5A,B), and MMP-2 activity
(Figure 5C,D) w re similar in tenocytes cu tured without coating (NC) or on MD-Tissue. By con rast,
gene expression for TIMP-1, the main inhibitor of MMP-1, was strongly affected by MD-Tissue.
In fact, gene expression was signific ntly up-regulated after 24 h (p < 0.05) and ten ed to a significant
up-re ulation after 72 h (p = 0.056) (Figure 6). Some interindividual differences in MMPs expression and
TIMP-1 mRNA levels were observed, showing unchang d, increased or decreased levels. However, a
strong correlation (p = 0.056) was observ d between MMP-1 protein levels and TIMP-1 gene expression
for tenocytes cultured on MD-Tissue at 72 h.
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Figure 6. Bar graphs showing tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) gene expression
after norm lization on GAPDH mRNA levels. Data obtained from the eight samples are xpressed as
mean ± SD. ×: mean.
3.3. Cytoskeleton Arra gement and Focal dhesion
Fluorescent microscopy analysis for F-actin (Figure 7A,B) revealed that actin filaments seem
unaffected by MD-Tissue. In both experimental conditions, they are long and mostly longitudinally
oriented in the cytoplasm.
In order to investigate whether MD-Tissue influences the ability of tenocytes to form focal
adhesions needed for cell migration, we analyzed the gene expression for vinculin (VCN) and Focal
adhesion kinase (FAK), key proteins involved in the formation of the adhesion plaque. VCN and
FAK mRNA levels, although with some interindividual differences, were unaffected by MD-Tissue
(Figure 7C,D). Immunofluorescence analysis for VCN shows that the protein is co-localized with
actin in correspondence of focal adhesion formation on the substrate, and many focal adhesions were
detectable in tenocytes cultured on either NC or MD-Tissue. Very frequently, the region corresponding
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to the presence of the focal adhesion seem bigger in tenocytes cultured on MD-Tissue compared to NC
tenocytes (see arrows in Figure 7B).
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Figure 7. Immunofluorescence analysis for vinculin (green) in control tenocytes (NC) (A) and tenocytes
cultured on MD-Tissue (B). Actin filaments are stained using rhodamine-phalloidin labeling. Nuclei are
stained in blue by DAPI. Original magnification: 60×. Bar graphs showing VCN (C) and FAK (D) gene
expression relative to GAPDH mRNA levels in NC and MD-Tissue tenocytes (COL). Data obtained
from the eight samples are expressed as mean ± SD. ×: mean; •: outlier sample.
3.4. Wound Healing Assay
o eali assay was used to analyze tenocyte migration f tenocytes cultured on MD-Tissue.
The comparison of the scratch size revealed that cell migration is significantly increased by MD-Tissue
(p < 0.05 vs. NC) (Figure 8).
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Figure 8. (A) Representative micrographs showing wound healing assay in control tenocytes (NC) and
tenocytes grown on MD-Tissue at 0 and 24 h after the scratch. Original magnification: 10×. (B) Bar
graphs showing the area of wound closure, expressed as a % of the area at 0 h, in cultured tenocytes in
both experimental conditions 24 h after the scratch. * p < 0.005 vs. NC. ×: mean.
4. Discussion
Treatment of tendinopathy, including Greater Trochanter Pain Syndrome and others, remain a big
problem for clinicians, because its pathogenesis is still largely misunderstood, and many treatments
have no real evidence. We aimed at characterizing in vitro the molecular mechanisms triggered in
human tenocytes by MD-Tissue®, and the main findings of this study reveal that this collagen-based
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injectable medical compound could favor tendon repair by inducing tenocyte proliferation and
migration, and stimulating COL-I synthesis, secretion and maturation.
Tendons play key functions in musculoskeletal system serving to transfer forces generated by
muscle contraction to the skeleton. Tendon mechanical properties are based on the underlying
extracellular matrix (ECM) structure and composition, mainly consisting of type I collagen (COL-I),
which constitutes about 60–85% of the dry mass of the tendon and about 95% of the total collagen,
and elastin, accounting for 1–2% [13–15]. Collagen and elastin are embedded in a ground substance
rich in proteoglycans, glycosaminoglycans, structural glycoproteins, and a wide variety of other small
molecules, having water-binding capacity and contributing to the stabilization of the whole tendon
structure. The unique structure and composition of tendons provide them the characteristic mechanical
stability, and COL-I represents the most important factor for tendon mechanical strength.
Tenocytes are tendon specialized fibroblasts interspersed between collagen fiber bundles and
aligned along the long axis of tendon, responsible for the synthesis and degradation of collagen and all
components of the ECM. Tenocytes act as mechanosensors playing key roles for the tendon’s adaptive
response and change their metabolic activities in response to mechanical forces acting on tendons,
modifying gene expression for ECM components and, as a consequence, affecting tendon’s mechanical
properties [14,16,17].
Tendon mechanical properties are based on its structure and composition, allowing tissue
mechanical adaptation in response to mechanical forces. Tenocytes are responsible for tendon
mechanical adaptation converting mechanical stimuli into biochemical signals that ultimately lead to
tendon adaptive physiological or pathological changes. Mechanical loads at physiological levels are
usually beneficial to tendons in terms of enhancing their mechanical properties [25–27], and increase
collagen synthesis [28]. Therefore, appropriate mechanical loads induce tendon adaptation and have
anabolic effects, improving their strength and healing quality after injury.
Collagen is the major component of tendon ECM; its turnover is controlled by tenocytes acting
at the level of collagen synthesis, maturation and degradation, thus determining the tendon ability
to resist mechanical forces and repair in response to injury [14]. Our data show that COL-I secretion
is significantly induced by MD-Tissue® at all considered time points, suggesting that this medical
compound is able to stimulate an anabolic phenotype of tenocytes. Newly synthesized collagen
undergoes cross-linking, that is an important requirement for collagen maturation providing tendon
strength, collagen fibril stabilization and increased tendon tensile strength [29,30]. Furthermore, our
data show that this particular medical compound is not able to affect gene expression for LH2b, needed
to provide cross-linking during collagen maturation, suggesting that collagen stability is not affected.
Since collagen content is the result of a finely regulated dynamic balance between its synthesis
and degradation driven by MMPs, tendon strength is strongly dependent on degradation pathways.
COL breakdown is played by MMP-1, able to cleave the intact collagen triple helix, followed by other
proteases [31,32]. The role of MMP-1 is boosted by the previously demonstrated inverse correlation
between MMP-1 gene/protein expression and the amplitude of tensile mechanical load on tendons,
suggesting that low levels of MMP-1 lead to a more stable and less susceptible to damage tendon
structure [33]. MMPs activation and activity are regulated by TIMPs [34,35], and TIMP-1 is the main
inhibitor of MMP-1. In this study, we show that MMP-1 and MMP-2 were unaffected by MD-Tissue®,
but, interestingly, we observed a significant increase in TIMP-1 gene expression induced by the medical
compound after 24 h, and a tendency to an up-regulation after 72 h. This result leads to the hypothesis
that MD-Tissue is able to stimulate COL secretion by tenocytes, increasing COL content in tendons,
and that COL increase is favored by inhibition of its degradation.
Some interindividual differences in fibroblast cell lines were observed, especially in LH2b mRNA,
MMPs and TIMP-1 mRNA. In fact, in some tenocytes the expression resulted unchanged, increased or
decreased. Interindividual differences were previously described in gingival fibroblasts, suggesting
the “cell subpopulation theory” [36] that described that the gingival fibroblast population is composed
of different subsets of fibroblasts that respond to external or endogenous stimuli in different way.
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Fibroblast heterogeneity was described also recently [37]. According to this theory, we can hypothesize
it is valid also for fibroblasts derived from different tissues, such as tenocytes.
ECM homeostasis is influenced by mechanical forces acting on tendons, and tenocytes are key
effectors in tendon ECM remodeling and adaptation to the experienced mechanical loading. They are
mechanoresponsive cells able to convert mechanical signals into biological events such as gene
expression and cell proliferation [38,39]. Tenocytes are able to sense changes in their mechanical
environment using a mechanotransduction system based on the actin cytoskeleton, and to respond
by modifying their activity [33]. Since actin cytoskeleton arrangement and integrity are the key
mechanotransduction apparatus influencing the tensional homeostasis and mechanoresponsiveness
needed to maintain ECM balance [40,41], we investigated whether MD-Tissue® affected actin
cytoskeleton. Our data show that actin filaments are brightly labelled and longitudinally running
in tenocytes cultured on plastic (NC) or on MD-Tissue®, and their arrangement is similar in both
experimental conditions, suggesting that this component of the mechanoresponsive apparatus is not
modified by the medical compound.
The actin cytoskeleton is also actively involved in cell migration, a dynamic process mediated
by a repeated cycle of attachment to the ECM, generation of cytoskeletal forces of propulsion, and
subsequent detachment of the cell from the matrix. The attachment of cells to the ECM is mediated
by integrins, transmembrane proteins that provide a bridge though which forces can be transmitted
between inside and outside of the cells. In fact, the extracellular domain of the integrin binds to
ECM components, whereas its cytoplasmic domain links various intracellular proteins interposed
between actin filaments and the integrin, forming focal adhesion complexes at the leading edge of the
cell [42]. Focal adhesions are not only involved in transmitting the mechanical signals from the ECM
into cells to modulate ECM remodeling; they are also necessary to generate the traction required for
cell migration [42]. We used a wound healing assay to investigate if tenocyte motility is affected by
MD-Tissue® since this test is particularly suitable to investigate the effects of cell–matrix interactions
on cell migration, mimicking in vivo cell migration [21], and we found that this medical compound
significantly increased cell migration. Interestingly, no difference in actin cytoskeleton between NC and
MD-Tissue tenocytes was detected, and also gene expression for FAK and VCN, two main components
of the focal adhesion complex, was similar in both experimental conditions, supporting the hypothesis
of a similar ability to form focal adhesions. However, interestingly, immunofluorescence analysis
of VCN expression revealed that focal adhesions containing VCN seem more evident in tenocytes
plated on MD-Tissue, leading to the hypothesis that MD-Tissue® could act as a mechanical scaffold
improving tenocyte focal adhesion, allowing a more efficient mechanoresponsiveness and migration
ability. This could make tenocytes more efficient in maintaining ECM homeostasis in response to
different mechanical load and in generating the traction necessary for cell migration [42]. Since the
process of tendon repair and regeneration is reliant on tenocyte migration [43], MD-Tissue® could
be effective in favoring tendon healing in tendinopathies, but clinical trials are needed to confirm
this suggestion.
A limit of this study is represented by the lacking of studies aimed at characterizing the
permanence and rheological and visco-elastic properties of MD-Tissue, however clinical studies
are available demonstrating that the collagen-based medical compound is effective in osteoarticular
pathologies [18,19].
MD-Tissue could offer some advantages compared to other biological agents since it can be
administered singularly or in association with other therapeutic agents and the reduced cost compared
to low or high MW HA could allow wider use, resulting in a NSAIDs intake reduction.
5. Conclusions
Considered as a whole, these in vitro findings suggest a mechanism for MD-Tissue likely acting as
a mechanical scaffold able to induce an anabolic phenotype in tenocytes, favoring tendon homeostasis
and repair. Interestingly, it was demonstrated [20] that the addition of acid-soluble type I collagen to
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fibroblasts cultured on plastic also affected collagen turnover mechanisms since some of the collagen
comes out of solution and precipitates on cell surfaces, still eliciting some effect nonmediated by a
cell-substrate interaction. This suggests that little mechanical resistance is sufficient to activate cell
receptors, influencing collagen turnover mechanisms and, very likely, other biological activities played
by tenocytes. We can hypothesize that MD-Tissue effect could be also mediated by this alternative
mechanism. Our results suggest that MD-Tissue® could represent a novel therapeutic approach, and
stimulate new clinical trials to investigate the effects of this medical compound to treat difficult tendon
pathologies. Based on our in vitro findings obtained on gluteal tenocytes, we will perform in future a
clinical trial to prove its utility on GTPS.
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